MarketLens
Sign Up

What Do the JADE101 Phase 1 Interim Results Reveal

4 months ago
SHARE THIS ON:

What Do the JADE101 Phase 1 Interim Results Reveal

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•1 day ago

MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026

MetaVia will present Phase 1 clinical trial data for DA-1726, a dual GLP-1/glucagon receptor agonist, in an oral presentation at the Precision Liver Symposium 2026 on November 4, 2026, in Denver.
Stock News•3 weeks ago

GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications

The oral GLP-1 market is projected to grow from $5.1B in 2026 to $89B in 2034, as Novo Nordisk reports additional weight loss in patients switching from injected to oral delivery.
Stock News•2 months ago

Jade Biosciences: Duration Is The Real Product

Jade Biosciences' JADE101 achieved ~70% IgA reduction in Phase 1 with favorable safety, targeting quarterly dosing for IgAN. Phase 2 JUNIPER interim data in 2027 will be pivotal, potentially improving...

Breaking News

View All →

Top Headlines

View More →
Stock News•59 minutes ago

Jim Cramer sees major implications from SK Hynix's home-run quarter

Stock News•1 hour ago

Google parent Alphabet tumbles after profit disappoints, warns AI is battering its cash flow

Stock News•1 hour ago

Jim Cramer says these tech giants can weather market turbulence

Stock News•1 hour ago

Alphabet Inc. (GOOG) Misses Q3 Earnings and Revenue Estimates

Stock News•1 hour ago

Alphabet (GOOGL) Q3 Earnings and Revenues Miss Estimates